SCYNEXIS Inc (SCYX)
1.845
+0.12
(+6.65%)
USD |
NASDAQ |
May 07, 16:00
1.845
0.00 (0.00%)
After-Hours: 19:03
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 69.66M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -42.14% |
Valuation | |
PE Ratio | 1.419 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.6369 |
Price to Book Value | 0.9547 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1666 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 94.28% |
Profile
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
URL | https://www.scynexis.com |
Investor Relations URL | http://ir.scynexis.com/index.cfm |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
URL | https://www.scynexis.com |
Investor Relations URL | http://ir.scynexis.com/index.cfm |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |